Neurogene reports FY2023 net loss $36.3M; Rett gene therapy trial expanded, cash runway to H2 2026

Neurogene Inc.

Cash and investments $197.2M at Dec 31, 2023; reverse merger and $95M private placement completed December 2023.
FY2023 net loss $36.3M vs $55.2M prior year; Q4 net income $2.4M from $16.4M bargain purchase gain.
R&D expenses $44.4M (down from $47.5M), G&A $11.2M (up from $9.0M) due to reverse merger costs.
Phase 1/2 NGN-401 Rett syndrome trial expanded with high-dose Cohort 2; interim clinical data expected 4Q24.
Appointed Dr. Julie Jordan as CMO; CLN5 Batten disease trial interim data and regulatory update expected H2 2024.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Neurogene Inc. reported year ended December 31, 2023 results: net income net loss was $36.3 million for the twelve months ended December 31, 2023.

Period: year ended December 31, 2023
Net income: net loss was $36.3 million for the twelve months ended December 31, 2023
Result: reported results

Exact text from the filing

Neurogene Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Updates

View on SEC.gov

21 earnings releases filed in the last 30 days. Browse all earnings releases →

Neurogene Inc. filing history →

Source: SEC EDGAR

accession 0001404644-24-000024

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.